Abstract
Get full access to this article
View all access options for this article.
References
1.
Kinsella
J
,
James
R
. Guidelines in the era of realistic medicine . J R Coll Physicians 2016 ; 46 : 74 –6 . https://dx-doi-org.web.bisu.edu.cn/10.4997/jrcpe.2016.201
2.
Bashir
S
,
Al-Mohammed
A
,
Gupta
S
. A practical approach to the new oral anticoagulants used for stroke prevention in patients with atrial fibrillation . J R Coll Physicians 2016 ; 46 : 113 –8 . https://dx-doi-org.web.bisu.edu.cn/10.4997/jrcpe.2016.211
3.
Kmietowicz
Z
. Boehringer Ingelheim withheld safety analyses on new anticoagulant, The BMJ investigation finds . BMJ 2014 ; 349 :g4756 . https://dx-doi-org.web.bisu.edu.cn/10.1136/bmj.g4756
4.
Moore
TJ
,
Cohen
MR
,
Mattison
DR
. Dabigatran, bleeding, and the regulators . BMJ 2014 ; 349 :g4517 . https://dx-doi-org.web.bisu.edu.cn/10.1136/bmj.g4517
5.
Cohen
D
. Rivaroxaban: can we trust the evidence? BMJ 2016 ; 352 :i575 . https://dx-doi-org.web.bisu.edu.cn/10.1136/bmj.i575
6.
Pirmohamed
M
,
Burnside
G
,
Eriksson
N
A randomized trial of genotype-guided dosing of warfarin . N Engl J Med 2013 ; 369 : 2294 –303 . https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa1311386
7.
Aithal
G
,
Day
C
,
Kesteven
P
,
Daly
A
. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications . Lancet 1999 ; 353 : 717 –9 .
8.
D'Andrea
G
,
Di Perna
P
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin . Blood 2005 ; 105 : 645 –9 .
9.
Klein
TE
,
Altman
RB
,
Eriksson
N
Estimation of the warfarin dose with clinical and pharmacogenetic data . N Engl J Med 2009 ; 360 : 753 –64 . https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa0809329
10.
Kimmel
SE
,
French
B
,
Kasner
SE
A pharmacogenetic versus a clinical algorithm for warfarin dosing . N Engl J Med 2013 ; 369 : 2283 –93 . https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa1310669